Biometry

Biometry

Biomarker-driven asthma management with patented sensors for personalized risk assessment and guideline-based self-management.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
-investor investor

€0.0

round
N/A

€0.0

round
investor

€0.0

round
investor

€0.0

round
investor

€0.0

round
*

$5.0m

Seed
Total Funding000k
More about Biometry
Made with AI
Edit

MyBiometry operates in the healthcare sector, focusing on asthma management through biomarker-driven insights. The company targets patients with asthma, providing them with actionable insights to lower their risk of attacks and improve asthma control. Utilizing patented sensors and devices, MyBiometry measures airway inflammation in breath via fractional exhaled nitric oxide (FeNO). This data is used to determine the risk of attacks, medication adherence, and exposure to environmental triggers. The business model revolves around delivering guideline-based coaching and education through a scalable app, recognized by the CDC for improving control and reducing costs. The app aggregates clinical and environmental risk factors to build personalized, predictive risk models for each patient. Revenue is generated through the provision of these services, which are scalable to millions of patients. The company leverages its own data to proactively engage patients before symptoms occur, aiming to improve self-management and reduce healthcare costs.

Keywords: asthma, biomarker, FeNO, sensors, risk assessment, self-management, healthcare, patients, app, coaching

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads